Advisors Asset Management Inc. Acquires 14,358 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Advisors Asset Management Inc. increased its stake in Gilead Sciences, Inc. by 6.4% during the first quarter, bringing its total holdings to about $26.9 million.
• Gilead Sciences reported earnings of $2.01 per share, beating the consensus estimate of $1.96, and its revenue for the quarter was $7.08 billion, exceeding expectations.
• The company declared a quarterly dividend of $0.79 per share, representing an annual yield of 2.8%, with the payout scheduled for September 29th.

Advisors Asset Management Inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 239,934 shares of the biopharmaceutical company's stock after purchasing an additional 14,358 shares during the quarter. Gilead Sciences accounts for about 0.5% of Advisors Asset Management Inc.'s holdings, making the stock its 25th biggest holding. Advisors Asset Management Inc.'s holdings in Gilead Sciences were worth $26,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of GILD. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $215,000. Aptus Capital Advisors LLC boosted its stake in shares of Gilead Sciences by 121.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 18,301 shares of the biopharmaceutical company's stock valued at $1,690,000 after purchasing an additional 10,038 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $3,214,000. Finally, Cary Street Partners Financial LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $586,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 2.0%

NASDAQ GILD traded up $2.28 during trading on Friday, hitting $115.05. The company had a trading volume of 6,953,644 shares, compared to its average volume of 5,536,983. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a one year low of $78.26 and a one year high of $121.83. The company has a market cap of $142.76 billion, a price-to-earnings ratio of 22.92, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company's fifty day moving average is $113.59 and its 200-day moving average is $109.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the business earned $2.01 EPS. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. UBS Group upped their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $115.39.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,371,330 over the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.